AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type & Geography (2019-2023) - ResearchAndMarkets.com

September 10, 2019

DUBLIN--(BUSINESS WIRE)--Sep 10, 2019--

The “Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and RoW.

In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy to stop the progression of the disease will play a significant role in the biologics segment to maintain its market position.

Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs. However, high treatment costs, stringent regulatory environment, and adverse side effects of DMD therapeutics may hamper the growth of the DMD therapeutics industry over the forecast period.

High unmet needs

Duchenne muscular dystrophy led to the identification of the dystrophin gene, which is responsible for coding patients that helps in maintaining muscle cell membrane stability. This led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. However, the high costs of these drugs are restricting their penetration in many underdeveloped and developing countries.

This has resulted in high unmet demand for affordable therapies that can reverse the progression of DMD. This is encouraging many leading vendors to introduce affordable novel therapies for the treatment. The strong distribution network of vendors coupled with the presence of reimbursement policies will lead to the expansion of the global Duchenne muscular dystrophy (DMD) therapeutics market at a CAGR of over 37% during the forecast period.

Increasing research funding

Advances in diagnostic methods is leading researchers and organizations to conduct research on developing therapeutics for treating DMD. For instance, Muscular Dystrophy Association developed an innovative way to fund the research on moving new drug targets into clinical stages at a fast pace.

On the other hand, organizations such as Duchenne UK provides research grants to vendors and researchers developing therapeutics for DMD. This increasing research funding is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading Duchenne muscular dystrophy (DMD) therapeutics manufacturers, that include:

Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

PART 14: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/sh0w7g

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005762/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 09/10/2019 10:24 AM/DISC: 09/10/2019 10:24 AM

http://www.businesswire.com/news/home/20190910005762/en

All contents © copyright 2019 The Associated Press. All rights reserved.